Non-TNF Biologic Beats Second Anti-TNF in Rheumatoid Arthritis

This article originally appeared here.
Share this content:
Non-TNF Biologic Beats Second Anti-TNF in Rheumatoid Arthritis
Non-TNF Biologic Beats Second Anti-TNF in Rheumatoid Arthritis

WEDNESDAY, Sept. 21, 2016 (HealthDay News) -- A non-tumor necrosis factor (TNF)-targeted biologic is more effective than a second anti-TNF drug for treatment of rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug, according to a study published in the Sept. 20 issue of the Journal of the American Medical Association.

Jacques-Eric Gottenberg, M.D., Ph.D., from the Strasbourg University Hospital in France, and colleagues randomized 300 patients with rheumatoid arthritis with persistent disease activity and an insufficient response to anti-TNF therapy to receive a non-TNF-targeted biologic agent or an anti-TNF that differed from their previous treatment. Overall, 89.7 percent of patients completed the study.

The researchers found that 69 percent of patients in the non-TNF group and 52 percent in the second anti-TNF group achieved a good or moderate European League Against Rheumatism response (odds ratio, 2.06). The non-TNF group had a lower disease activity score in 28 joints-erythrocyte sedimentation rate than in the second anti-TNF group (mean difference, −0.43). More patients in the non-TNF group showed low disease activity at weeks 24 and 52 (odds ratio, 2.09 and 2.26, respectively).

"Among patients with rheumatoid arthritis previously treated with anti-TNF drugs but with inadequate primary response, a non-TNF biologic agent was more effective in achieving a good or moderate disease activity response at 24 weeks than was the second anti-TNF medication," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NTproBNP Levels Are Significantly Lower in Blacks

NTproBNP Levels Are Significantly Lower in Blacks

Higher NTproBNP levels linked to increased risk of death; this association did not differ by race

Data May Weigh on Pros/Cons of Expanded Care Optometry

Data May Weigh on Pros/Cons of Expanded Care ...

Majority of residents in Kentucky, Oklahoma, New Mexico live within 30 minutes of ophthalmologist

Gaps Seen Between Hearing Loss, Receipt of Medical Evaluation, Tx

Gaps Seen Between Hearing Loss, Receipt of Medical ...

About 20.6 percent of those with hearing less than excellent/good had visited doctor for hearing issues

is free, fast, and customized just for you!

Already a member?

Sign In Now »